

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
13 July 2006 (13.07.2006)

PCT

(10) International Publication Number
WO 2006/073361 A1

(51) International Patent Classification:

C07D 401/04 (2006.01) **C07D 409/12** (2006.01)
A61K 31/4427 (2006.01) **C07D 409/14** (2006.01)
A61P 7/02 (2006.01) **C07D 413/12** (2006.01)
C07D 213/78 (2006.01) **C07D 413/14** (2006.01)
C07D 401/14 (2006.01)

(SE). ÖSTERLUND, Krister [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/SE2006/000010

(22) International Filing Date: 4 January 2006 (04.01.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0500140.9 6 January 2005 (06.01.2005) GB
 0521484.6 21 October 2005 (21.10.2005) GB

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BACH, Peter** [DK/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **BOSTRÖM, Jonas** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **BRICKMANN, Kay** [DE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **CHENG, Leifeng** [GB/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **GIORDANETTO, Fabrizio** [IT/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **GRONEBERG, Robert D.** [US/US]; 958 Yellow Pine Ave, Boulder, Colorado 80304 (US). **HARVEY, Darren, Martin** [US/US]; 10225 King Street, Westminster, Colorado 80031 (US). **O'SULLIVAN, Michael, F.** [US/US]; 20 South Boulder Circle #2203, Boulder, CO 80303 (US). **ZETTERBERG, Fredrik** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) Date of publication of this corrected version:


2 August 2007

(15) Information about Correction:

see PCT Gazette No. 31/2007 of 2 August 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL PYRIDINE COMPOUNDS



(I)

(57) Abstract: The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.